The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond

Therapeutic Advances in Hematology - Tập 5 Số 3 - Trang 65-77 - 2014
Seth A. Wander1, Mark J. Levis2, Amir Fathi3
1Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
2Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
3Massachusetts General Hospital, Harvard Medical School, Zero Emerson Place, Suite 118, Boston, MA 02114, USA

Tóm tắt

Acute myeloid leukemia remains associated with poor outcomes despite advances in our understanding of the complicated molecular events driving leukemogenesis and malignant progression. Those patients harboring mutations in the FLT3 receptor tyrosine kinase have a particularly poor prognosis; however, significant excitement has been generated by the emergence of a variety of targeted inhibitors capable of suppressing FLT3 signaling in vivo. Here we will review results from preclinical studies and early clinical trials evaluating both first- and second-generation FLT3 inhibitors. Early FLT3 inhibitors (including sunitinib, midostaurin, and lestaurtinib) demonstrated significant promise in preclinical models of FLT3 mutant AML. Unfortunately, many of these compounds failed to achieve robust and sustained FLT3 inhibition in early clinical trials, at best resulting in only transient decreases in peripheral blast counts. These results have prompted the development of second-generation FLT3 inhibitors, epitomized by the novel agent quizartinib. These second-generation inhibitors have demonstrated enhanced FLT3 specificity and have been generally well tolerated in early clinical trials. Several FLT3 inhibitors have reached phase III clinical trials, and a variety of phase I/II trials exploring a role for these novel compounds in conjunction with conventional chemotherapy or hematopoietic stem cell transplantation are ongoing. Finally, molecular insights provided by FLT3 inhibitors have shed light upon the variety of mechanisms underlying the acquisition of resistance and have provided a rationale supporting the use of combinatorial regimens with other emerging targeted therapies.

Từ khóa


Tài liệu tham khảo

10.1046/j.1365-2141.2001.02850.x

Bar-Natan M., 2012, JAKSTAT, 1, 55

10.1182/blood.V118.21.3632.3632

10.1159/000134046

10.1182/blood.V87.3.1089.bloodjournal8731089

10.1200/JCO.2013.48.8783

Cortes J., 2012, Blood, 120

10.1016/S0140-6736(06)69446-4

10.1056/NEJMoa060655

10.1182/blood-2013-01-478172

10.1182/blood.V120.21.1483.1483

10.1182/blood-2004-05-1846

10.1200/JCO.2010.28.9678

10.1158/1538-7445.AM2012-3660

10.1182/blood-2007-08-109090

10.1182/blood-2002-02-0492

10.1053/j.seminoncol.2006.04.002

10.1089/15258160260090997

10.1101/gad.1212704

10.1182/blood-2005-06-2469

Howlader N., Noone A., Krapcho M., Garshell J., Neyman N., Altekruse S. (2013) SEER Stat Fact Sheets: Acute Myeloid Leukemia. http://seer.cancer.gov/csr/1975_2010/

10.1186/1476-4598-12-19

Kayser S., 2013, Leuk Lymphoma

10.1182/blood-2009-03-209999

10.1146/annurev.genom.3.032802.115046

10.1038/sj.leu.2401130

10.1182/blood-2006-04-015560

Levis M., 2012, Blood, 120, 10.1182/blood.V120.21.673.673

10.1182/blood-2010-08-301796

10.1038/sj.leu.2403099

10.1056/NEJMoa1301689

10.1056/NEJMoa0708857

10.1056/NEJM199909303411407

10.1182/blood.V83.10.2795.2795

10.1016/j.cell.2007.06.009

10.1200/JCO.2010.30.2554

10.1093/annonc/mdp347

10.1038/leu.2012.105

10.1038/leu.2012.52

Moreno I., 2003, Haematologica, 88, 19

10.1056/NEJMoa065044

Nakao M., 1996, Leukemia, 10, 1911

O’Farrell A., 2003, Clin Cancer Res, 9, 5465

10.1158/0008-5472.CAN-10-4136

10.1182/blood-2006-05-023804

10.1038/leu.2010.132

10.1182/blood-2009-09-242859

10.1182/blood-2013-01-480228

10.1200/JCO.2009.25.4888

Rosnet O., 1996, Leukemia, 10, 238

10.1128/MMBR.68.2.320-344.2004

10.1182/blood-2010-01-266742

10.1002/gcc.21975

10.1038/leu.2011.97

Serve H., 2010, Blood (ASH Annual Meeting Abstracts), 116

10.1182/blood-2012-01-402545

10.1016/j.bbmt.2011.07.011

10.1073/pnas.91.2.459

10.1182/blood-2003-11-3775

10.1038/nature11016

10.1182/blood-2005-08-3453

10.1182/blood-2004-03-0891

10.1038/leu.2012.115

10.1182/blood.V99.12.4326

10.1146/annurev.cb.10.110194.001343

10.1158/0008-5472.CAN-08-2923

10.1172/JCI44145

10.1038/leu.2012.96

10.1371/journal.pone.0056473

10.1182/blood.V97.8.2434

Yang X., 2011, Blood, 118

10.1182/blood-2009-05-222034

10.1093/jnci/djm328

10.1182/blood-2008-05-156422

10.1182/blood-2013-07-513044

Thông tin
Thông tin xuất bản

Therapeutic Advances in Hematology

Tập 5 Số 3

65-77

Thông tin tác giả